Clinical Trials Logo

Dedifferentiated Liposarcoma clinical trials

View clinical trials related to Dedifferentiated Liposarcoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04979442 Terminated - Clinical trials for Dedifferentiated Liposarcoma

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

MANTRA
Start date: July 14, 2021
Phase: Phase 3
Study type: Interventional

Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

NCT ID: NCT03604783 Terminated - Sarcoma Clinical Trials

Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors

Start date: December 26, 2018
Phase: Phase 1
Study type: Interventional

TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-1287 in patients with advanced metastatic or progressive solid tumors who are refractory to, or intolerant of, established therapy known to provide clinical benefit for their condition.